Lit Matters 1: Is 4-FPCC Safe or Efficacious for Trauma Patients Needing MTP?

Trauma hemorrhage is lethal partly because acute traumatic coagulopathy is hard to reverse in real time. In patients at risk for massive transfusion, early 4-factor prothrombin complex concentrate did not reduce 24-hour blood product use and was associated with more venous thromboembolism.

4F-PCC in Trauma MTP

• Acute coagulopathy target: 4F-PCC packages factors II, VII, IX, and X into a rapid, low-volume concentrate, making it an appealing fix for trauma-induced coagulopathy when MTP is already underway.
• Massive transfusion population: The trial focused on highest-level trauma activations with ongoing transfusion needs plus an Assessment of Blood Consumption score of at least 2, a practical shorthand for early hemorrhage risk.
• Primary efficacy result: Early 4F-PCC did not lower total 24-hour use of RBCs, plasma, and platelets compared with placebo, despite otherwise contemporary trauma hemorrhage care.
• Secondary outcomes signal: There was no improvement in time to prothrombin time ratio normalization, hemorrhage control, or 24-hour and 28-day mortality. We get into why that matters clinically in the episode.
• Safety concern: Venous thromboembolism was more common with 4F-PCC, with 56 events versus 37 in placebo, a clinically important harm signal that outweighs any hoped-for transfusion benefit.
• Practice takeaway: For trauma patients at risk for massive transfusion, routine early 4F-PCC is hard to justify outside narrow exceptions, especially when balanced against the thrombosis signal seen here.